10. REFERENCES
1.Masson-Lecomte, A., et al. EAU Guidelines on Urothelial Carcinomas of the Upper Urinary Tract. 2024. Edn. presented at the 38th EAU Annual Congress Paris 2024.
https://uroweb.org/guidelines/upper-urinary-tract-urothelial-cell-carcinoma
2.Witjes, J., et al. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. 2024. Edn. presented at the 38th EAU Annual Congress Paris 2024.
https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/references
3.Neuzillet, Y., et al. EAU Guidelines on Primary Urethral Carcinoma. 2024. Edn. presented at the 38th EAU Annual Congress Paris 2024.
https://uroweb.org/guidelines/primary-urethral-carcinoma
4.Babjuk, M., et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol, 2022. 81: 75.
https://www.ncbi.nlm.nih.gov/pubmed/34511303
5.Phillips, B. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009. 1998.
6.Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049.
https://www.ncbi.nlm.nih.gov/pubmed/18467413
7.International Agency for Research on Cancer. Estimated number of new cases in 2020, worldwide, both sexes, all ages. World Health Organization. 2021.
https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&group_cancer=1&include_nmsc=1&include_nmsc_other=1
8.Burger, M., et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol, 2013. 63: 234.
https://www.ncbi.nlm.nih.gov/pubmed/22877502
9.Teoh, J.Y., et al. Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. Eur Urol, 2020. 78: 893.
https://www.ncbi.nlm.nih.gov/pubmed/32972792
10.Comperat, E., et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch, 2015. 466: 589.
https://www.ncbi.nlm.nih.gov/pubmed/25697540
11.Freedman, N.D., et al. Association between smoking and risk of bladder cancer among men and women. JAMA, 2011. 306: 737.
https://www.ncbi.nlm.nih.gov/pubmed/21846855
12.Laaksonen, M.A., et al. The future burden of kidney and bladder cancers preventable by behavior modification in Australia: A pooled cohort study. Int J Cancer, 2020. 146: 874.
https://www.ncbi.nlm.nih.gov/pubmed/31107541
13.van Osch, F.H., et al. Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. Int J Epidemiol, 2016. 45: 857.
https://www.ncbi.nlm.nih.gov/pubmed/27097748
14.Bjurlin, M.A., et al. Carcinogen Biomarkers in the Urine of Electronic Cigarette Users and Implications for the Development of Bladder Cancer: A Systematic Review. Eur Urol Oncol, 2021. 4: 766.
https://www.ncbi.nlm.nih.gov/pubmed/32192941
15.Colt, J.S., et al. A case-control study of occupational exposure to metalworking fluids and bladder cancer risk among men. Occup Environ Med, 2014. 71: 667.
https://www.ncbi.nlm.nih.gov/pubmed/25201311
16.Pesch, B., et al. Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines. Int Arch Occup Environ Health, 2014. 87: 715.
https://www.ncbi.nlm.nih.gov/pubmed/24129706
17.Koutros, S., et al. Diesel exhaust and bladder cancer risk by pathologic stage and grade subtypes. Environ Int, 2020. 135: 105346.
https://www.ncbi.nlm.nih.gov/pubmed/31864026
18.Kayyal-Tarabeia, I., et al. Residence near industrial complex and cancer incidence: A registry-based cohort of 1,022,637 participants with a follow-up of 21 years, Israel. Environ Res, 2023. 216: 114471.
https://www.ncbi.nlm.nih.gov/pubmed/36208787
19.Egbers, L., et al. The prognostic value of family history among patients with urinary bladder cancer. Int J Cancer, 2015. 136: 1117.
https://www.ncbi.nlm.nih.gov/pubmed/24978702
20.Corral, R., et al. Comprehensive analyses of DNA repair pathways, smoking and bladder cancer risk in Los Angeles and Shanghai. Int J Cancer, 2014. 135: 335.
https://www.ncbi.nlm.nih.gov/pubmed/24382701
21.Figueroa, J.D., et al. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Hum Mol Genet, 2016. 25: 1203.
https://www.ncbi.nlm.nih.gov/pubmed/26732427
22.Zhong, J.H., et al. Association between APE1 Asp148Glu polymorphism and the risk of urinary cancers: a meta-analysis of 18 case-control studies. Onco Targets Ther, 2016. 9: 1499.
https://www.ncbi.nlm.nih.gov/pubmed/27042118
23.Al-Zalabani, A.H., et al. Modifiable risk factors for the prevention of bladder cancer: a systematic review of meta-analyses. Eur J Epidemiol, 2016. 31: 811.
https://www.ncbi.nlm.nih.gov/pubmed/27000312
24.Wu, J., et al. A Functional rs353293 Polymorphism in the Promoter of miR-143/145 Is Associated with a Reduced Risk of Bladder Cancer. PLoS One, 2016. 11: e0159115.
https://www.ncbi.nlm.nih.gov/pubmed/27438131
25.Martin, C., et al. Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. J Natl Cancer Inst, 2018. 110: 527.
https://www.ncbi.nlm.nih.gov/pubmed/29228305
26.Yu, E.Y., et al. Family History and Risk of Bladder Cancer: An Analysis Accounting for First- and Second-degree Relatives. Cancer Prev Res (Phila), 2022. 15: 319.
https://www.ncbi.nlm.nih.gov/pubmed/35027464
27.Lenfant, L., et al. Genetic variability in 13q33 and 9q34 is linked to aggressiveness patterns and a higher risk of progression of non-muscle-invasive bladder cancer at the time of diagnosis. BJU Int, 2021. 127: 375.
https://www.ncbi.nlm.nih.gov/pubmed/32975901
28.Rossi, M., et al. Flavonoids and bladder cancer risk. Cancer Causes Control, 2019. 30: 527.
https://www.ncbi.nlm.nih.gov/pubmed/30903485
29.Buckland, G., et al. Adherence to the Mediterranean diet and risk of bladder cancer in the EPIC cohort study. Int J Cancer, 2014. 134: 2504.
https://www.ncbi.nlm.nih.gov/pubmed/24226765
30.Liu, H., et al. Fruit and vegetable consumption and risk of bladder cancer: an updated meta-analysis of observational studies. Eur J Cancer Prev, 2015. 24: 508.
https://www.ncbi.nlm.nih.gov/pubmed/25642791
31.Vieira, A.R., et al. Fruits, vegetables, and bladder cancer risk: a systematic review and meta-analysis. Cancer Med, 2015. 4: 136.
https://www.ncbi.nlm.nih.gov/pubmed/25461441
32.Zhao, L., et al. Association of body mass index with bladder cancer risk: a dose-response meta-analysis of prospective cohort studies. Oncotarget, 2017. 8: 33990.
https://www.ncbi.nlm.nih.gov/pubmed/28389625
33.Witlox, W.J.A., et al. An inverse association between the Mediterranean diet and bladder cancer risk: a pooled analysis of 13 cohort studies. Eur J Nutr, 2020. 59: 287.
https://www.ncbi.nlm.nih.gov/pubmed/30737562
34.Dianatinasab, M., et al. Dietary fats and their sources in association with the risk of bladder cancer: A pooled analysis of 11 prospective cohort studies. Int J Cancer, 2022. 151: 44.
https://www.ncbi.nlm.nih.gov/pubmed/35182086
35.Dianatinasab, M., et al. The association between meat and fish consumption and bladder cancer risk: a pooled analysis of 11 cohort studies. Eur J Epidemiol, 2021. 36: 781.
https://www.ncbi.nlm.nih.gov/pubmed/34036467
36.Jochems, S.H.J., et al. Fruit consumption and the risk of bladder cancer: A pooled analysis by the Bladder Cancer Epidemiology and Nutritional Determinants Study. Int J Cancer, 2020. 147: 2091.
https://www.ncbi.nlm.nih.gov/pubmed/32285440
37.Boot, I.W.A., et al. Dietary B group vitamin intake and the bladder cancer risk: a pooled analysis of prospective cohort studies. Eur J Nutr, 2022. 61: 2397.
https://www.ncbi.nlm.nih.gov/pubmed/35129646
38.Al-Zalabani, A.H., et al. Tea consumption and risk of bladder cancer in the Bladder Cancer Epidemiology and Nutritional Determinants (BLEND) Study: Pooled analysis of 12 international cohort studies. Clin Nutr, 2022. 41: 1122.
https://www.ncbi.nlm.nih.gov/pubmed/35413574
39.Steinmaus, C., et al. Increased lung and bladder cancer incidence in adults after in utero and early-life arsenic exposure. Cancer Epidemiol Biomarkers Prev, 2014. 23: 1529.
https://www.ncbi.nlm.nih.gov/pubmed/24859871
40.Koutros, S., et al. Potential effect modifiers of the arsenic-bladder cancer risk relationship. Int J Cancer, 2018. 143: 2640.
https://www.ncbi.nlm.nih.gov/pubmed/29981168
41.Arafa, A., et al. Chronic exposure to nitrate in drinking water and the risk of bladder cancer: a meta-analysis of epidemiological evidence. Public Health, 2022. 203: 123.
https://www.ncbi.nlm.nih.gov/pubmed/35063929
42.Zhang, Y., et al. Personal use of permanent hair dyes and cancer risk and mortality in US women: prospective cohort study. BMJ, 2020. 370: m2942.
https://www.ncbi.nlm.nih.gov/pubmed/32878860
43.Moschini, M., et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol, 2019. 75: 319.
https://www.ncbi.nlm.nih.gov/pubmed/30293908
44.Minami, T., et al. External beam radiotherapy combination is a risk factor for bladder cancer in patients with prostate cancer treated with brachytherapy. World J Urol, 2023. 41: 1317.
https://www.ncbi.nlm.nih.gov/pubmed/37024557
45.Teleka, S., et al. Risk of bladder cancer by disease severity in relation to metabolic factors and smoking: A prospective pooled cohort study of 800,000 men and women. Int J Cancer, 2018. 143: 3071.
https://www.ncbi.nlm.nih.gov/pubmed/29756343
46.Hektoen, H.H., et al. Vitamin D and Vitamin D-binding protein and risk of bladder cancer: A nested case-control study in the Norwegian Janus Serum Bank Cohort. Cancer Med, 2021. 10: 4107.
https://www.ncbi.nlm.nih.gov/pubmed/34080787
47.Tuccori, M., et al. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ, 2016. 352: i1541.
https://www.ncbi.nlm.nih.gov/pubmed/27029385
48.Otto, W., et al. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach. Int Urol Nephrol, 2017. 49: 431.
https://www.ncbi.nlm.nih.gov/pubmed/28035618
49.van Rhijn, B.W., et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol, 2012. 61: 378.
https://www.ncbi.nlm.nih.gov/pubmed/22036775
50.Comperat, E., et al. What’s new in WHO fifth edition - urinary tract. Histopathology, 2022. 81: 439.
https://www.ncbi.nlm.nih.gov/pubmed/35942645
51.WHO Classification of Tumours Editorial Board. WHO Classification of Tumours. Urinary and male genital tumours. International Agency for Research on Cancer 5th Edn.; Vol 8. 2022.
https://publications.iarc.fr/610
52.Moch, H., et al. WHO Classification of Tumours of the Urinary System and Male Genital Organs. International Agency for Research on Cancer 4th Edn. 2016.
53.Comperat, E., et al. The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Adv Anat Pathol, 2021. 28: 196.
https://www.ncbi.nlm.nih.gov/pubmed/34128484
54.Kim, H.S., et al. Presence of lymphovascular invasion in urothelial bladder cancer specimens after transurethral resections correlates with risk of upstaging and survival: a systematic review and meta-analysis. Urol Oncol, 2014. 32: 1191.
https://www.ncbi.nlm.nih.gov/pubmed/24954108
55.Tilki, D., et al. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU Int, 2013. 111: 1215.
https://www.ncbi.nlm.nih.gov/pubmed/23181623
56.Martin-Doyle, W., et al. Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol, 2015. 33: 643.
https://www.ncbi.nlm.nih.gov/pubmed/25559810
57.Mari, A., et al. A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. BJU Int, 2019. 123: 11.
https://www.ncbi.nlm.nih.gov/pubmed/29807387
58.D, D.A., et al. Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool. Urol Oncol, 2018. 36: 239 e1.
https://www.ncbi.nlm.nih.gov/pubmed/29506941
59.Sauter G, A.F., Amin M, et al. . Tumours of the urinary system: non-invasive urothelial neoplasias. In: WHO classification of classification of tumours of the urinary system and male genital organs. IARCC Press, 2004: 29.
60.Soukup, V., et al. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. Eur Urol, 2017. 72: 801.
https://www.ncbi.nlm.nih.gov/pubmed/28457661
61.Mariappan, P., et al. Combining two grading systems: the clinical validity and inter-observer variability of the 1973 and 2004 WHO bladder cancer classification systems assessed in a UK cohort with 15 years of prospective follow-up. World J Urol, 2021. 39: 425.
https://www.ncbi.nlm.nih.gov/pubmed/32266509
62.Hentschel, A.E., et al. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019? Urol Oncol, 2020. 38: 440.
https://www.ncbi.nlm.nih.gov/pubmed/31704141
63.van Rhijn, B.W.G., et al. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. Eur Urol Oncol, 2021. 4: 182.
https://www.ncbi.nlm.nih.gov/pubmed/33423944
64.Andersson, M., et al. The diagnostic challenge of suspicious or positive malignant urine cytology findings when cystoscopy findings are normal: an outpatient blue-light flexible cystoscopy may solve the problem. Scand J Urol, 2021. 55: 263.
https://www.ncbi.nlm.nih.gov/pubmed/34037496
65.Lamm, D., et al. Updated concepts and treatment of carcinoma in situ. Urol Oncol, 1998. 4: 130.
https://www.ncbi.nlm.nih.gov/pubmed/21227218
66.Witjes, J.A., et al. Review pathology in a diagnostic bladder cancer trial: effect of patient risk category. Urology, 2006. 67: 751.
https://www.ncbi.nlm.nih.gov/pubmed/16566990
67.May, M., et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol, 2010. 57: 850.
https://www.ncbi.nlm.nih.gov/pubmed/19346063
68.van Rhijn, B.W., et al. Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int, 2010. 106: 206.
https://www.ncbi.nlm.nih.gov/pubmed/20002439
69.Comperat, E., et al. An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. Histopathology, 2013. 63: 756.
https://www.ncbi.nlm.nih.gov/pubmed/24102813
70.Mangrud, O.M., et al. Reproducibility and prognostic value of WHO1973 and WHO2004 grading systems in TaT1 urothelial carcinoma of the urinary bladder. PLoS One, 2014. 9: e83192.
https://www.ncbi.nlm.nih.gov/pubmed/24409280
71.Veskimae, E., et al. What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. Eur Urol Oncol, 2019. 2: 625.
https://www.ncbi.nlm.nih.gov/pubmed/31601522
72.Comperat, E.M., et al. Grading of Urothelial Carcinoma and The New “World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016”. Eur Urol Focus, 2019. 5: 457.
https://www.ncbi.nlm.nih.gov/pubmed/29366854
73.Willis, D.L., et al. Clinical outcomes of cT1 micropapillary bladder cancer. J Urol, 2015. 193: 1129.
https://www.ncbi.nlm.nih.gov/pubmed/25254936
74.Comperat, E., et al. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology, 2010. 42: 650.
https://www.ncbi.nlm.nih.gov/pubmed/21080874
75.Kaimakliotis, H.Z., et al. Plasmacytoid variant urothelial bladder cancer: is it time to update the treatment paradigm? Urol Oncol, 2014. 32: 833.
https://www.ncbi.nlm.nih.gov/pubmed/24954925
76.Willis, D.L., et al. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol Oncol, 2014. 32: 826.
https://www.ncbi.nlm.nih.gov/pubmed/24931270
77.Beltran, A.L., et al. Clinicopathological characteristics and outcome of nested carcinoma of the urinary bladder. Virchows Arch, 2014. 465: 199.
https://www.ncbi.nlm.nih.gov/pubmed/24878757
78.Soave, A., et al. Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy? Urol Oncol, 2015. 33: 21 e1.
https://www.ncbi.nlm.nih.gov/pubmed/25465301
79.Masson-Lecomte, A., et al. Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy. World J Urol, 2015. 33: 1087.
https://www.ncbi.nlm.nih.gov/pubmed/25179011
80.Seisen, T., et al. Impact of histological variants on the outcomes of nonmuscle invasive bladder cancer after transurethral resection. Curr Opin Urol, 2014. 24: 524.
https://www.ncbi.nlm.nih.gov/pubmed/25051021
81.Burger, M., et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol, 2008. 54: 835.
https://www.ncbi.nlm.nih.gov/pubmed/18166262
82.Fristrup, N., et al. Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol, 2012. 180: 1824.
https://www.ncbi.nlm.nih.gov/pubmed/22449953
83.Palou, J., et al. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guerin. Eur Urol, 2009. 56: 829.
https://www.ncbi.nlm.nih.gov/pubmed/18926620
84.van Rhijn, B.W., et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol, 2012. 187: 310.
https://www.ncbi.nlm.nih.gov/pubmed/22099989
85.Remy, E., et al. A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis. Cancer Res, 2015. 75: 4042.
https://www.ncbi.nlm.nih.gov/pubmed/26238783
86.Dyrskjot, L., et al. Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study. Eur Urol, 2017. 72: 461.
https://www.ncbi.nlm.nih.gov/pubmed/28583312
87.Marzouka, N.A., et al. The Lund Molecular Taxonomy Applied to Non-Muscle-Invasive Urothelial Carcinoma. J Mol Diagn, 2022. 24: 992.
https://www.ncbi.nlm.nih.gov/pubmed/35853574
88.Ramirez, D., et al. Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer. BJU Int, 2016. 117: 783.
https://www.ncbi.nlm.nih.gov/pubmed/26435378
89.Trinh, T.W., et al. Bladder cancer diagnosis with CT urography: test characteristics and reasons for false-positive and false-negative results. Abdom Radiol (NY), 2018. 43: 663.
https://www.ncbi.nlm.nih.gov/pubmed/28677000
90.Nolte-Ernsting, C., et al. Understanding multislice CT urography techniques: Many roads lead to Rome. Eur Radiol, 2006. 16: 2670.
https://www.ncbi.nlm.nih.gov/pubmed/16953373
91.Goessl, C., et al. Is routine excretory urography necessary at first diagnosis of bladder cancer? J Urol, 1997. 157: 480.
https://www.ncbi.nlm.nih.gov/pubmed/8996338
92.Palou, J., et al. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol, 2005. 174: 859.
https://www.ncbi.nlm.nih.gov/pubmed/16093970
93.Holmang, S., et al. Long-term followup of a bladder carcinoma cohort: routine followup urography is not necessary. J Urol, 1998. 160: 45.
https://www.ncbi.nlm.nih.gov/pubmed/9628602
94.Millan-Rodriguez, F., et al. Upper urinary tract tumors after primary superficial bladder tumors: prognostic factors and risk groups. J Urol, 2000. 164: 1183.
https://www.ncbi.nlm.nih.gov/pubmed/10992362
95.Tan, W.S., et al. Can Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria? J Urol, 2018. 200: 973.
https://www.ncbi.nlm.nih.gov/pubmed/29702097
96.Hilton, S., et al. Recent advances in imaging cancer of the kidney and urinary tract. Surg Oncol Clin N Am, 2014. 23: 863.
https://www.ncbi.nlm.nih.gov/pubmed/25246053
97.Panebianco, V., et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol, 2018. 74: 294.
https://www.ncbi.nlm.nih.gov/pubmed/29755006
98.Del Giudice, F., et al. Systematic Review and Meta-Analysis of Vesical Imaging-Reporting and Data System (VI-RADS) Inter-Observer Reliability: An Added Value for Muscle Invasive Bladder Cancer Detection. Cancers (Basel), 2020. 12: 2994.
https://www.ncbi.nlm.nih.gov/pubmed/33076505
99.Yafi, F.A., et al. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol, 2015. 33: 66 e25.
https://www.ncbi.nlm.nih.gov/pubmed/25037483
100.Tetu, B. Diagnosis of urothelial carcinoma from urine. Mod Pathol, 2009. 22 Suppl 2: S53.
https://www.ncbi.nlm.nih.gov/pubmed/19494853
101.Lobo, J., et al. Evaluation of the Implementation and Diagnostic Accuracy of the Paris Classification for Reporting Urinary Cytology in Voided Urine Specimens: A Cyto-Histological Correlation Study in a Cancer Center. Pathobiology, 2023. 90: 233.
https://www.ncbi.nlm.nih.gov/pubmed/36574757
102.Raitanen, M.P., et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol, 2002. 41: 284.
https://www.ncbi.nlm.nih.gov/pubmed/12180229
103.Karakiewicz, P.I., et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int, 2006. 97: 997.
https://www.ncbi.nlm.nih.gov/pubmed/16542342
104.Tian, W., et al. Significant reduction of indeterminate (atypical) diagnosis after implementation of The Paris System for Reporting Urinary Cytology: A single-institution study of more than 27,000 cases. Cancer Cytopathol, 2021. 129: 114.
https://www.ncbi.nlm.nih.gov/pubmed/32931158
105.Lebret, T., et al. Artificial intelligence to improve cytology performances in bladder carcinoma detection: results of the VisioCyt test. BJU Int, 2022. 129: 356.
https://www.ncbi.nlm.nih.gov/pubmed/33751774
106.Wojcik, E.M., Kurtycz, D.F.I., Rosenthal, D.L., The Paris System for Reporting Urinary Cytology, ed. E.M. Wojcik, Kurtycz, DFI, Rosenthal, D.L., Eds. Vol. 2nd Edn. . 2022.
https://link.springer.com/book/10.1007/978-3-030-88686-8
107.Pastorello, R.G., et al. Experience on the use of The Paris System for Reporting Urinary Cytopathology: review of the published literature. J Am Soc Cytopathol, 2021. 10: 79.
https://www.ncbi.nlm.nih.gov/pubmed/33160893
108.Meilleroux, J., et al. One year of experience using the Paris System for Reporting Urinary Cytology. Cancer Cytopathol, 2018. 126: 430.
https://www.ncbi.nlm.nih.gov/pubmed/29663682
109.Nabi, G., et al. Suspicious urinary cytology with negative evaluation for malignancy in the diagnostic investigation of haematuria: how to follow up? J Clin Pathol, 2004. 57: 365.
https://www.ncbi.nlm.nih.gov/pubmed/15047737
110.Soria, F., et al. An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer. World J Urol, 2018. 36: 1981.
https://www.ncbi.nlm.nih.gov/pubmed/29931526
111.Moulavasilis, N., et al. The Paris system classification for urinary cytology in patients under bacillus Calmette-Guerin treatment. Diagn Cytopathol, 2022. 50: 289.
https://www.ncbi.nlm.nih.gov/pubmed/35262275
112.D’Andrea, D., et al. Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer. BJU Int, 2019. 123: 959.
https://www.ncbi.nlm.nih.gov/pubmed/30653818
113.Ribal, M.J., et al. Gene expression test for the non-invasive diagnosis of bladder cancer: A prospective, blinded, international and multicenter validation study. Eur J Cancer, 2016. 54: 131.
https://www.ncbi.nlm.nih.gov/pubmed/26761785
114.Konety, B., et al. Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy. Eur Urol, 2019. 76: 238.
https://www.ncbi.nlm.nih.gov/pubmed/31103391
115.Kavalieris, L., et al. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. J Urol, 2017. 197: 1419.
https://www.ncbi.nlm.nih.gov/pubmed/27986532
116.Gontero, P., et al. Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study. BJU Int, 2021. 127: 198.
https://www.ncbi.nlm.nih.gov/pubmed/32745350
117.Roupret, M., et al. Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non-muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker. Eur Urol Focus, 2022. 8: 1643.
https://www.ncbi.nlm.nih.gov/pubmed/35300937
118.Cancel-Tassin, G., et al. Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up. World J Urol, 2021. 39: 3329.
https://www.ncbi.nlm.nih.gov/pubmed/33770241
119.Singer, G., et al. The Role of New Technologies in the Diagnosis and Surveillance of Non-Muscle Invasive Bladder Carcinoma: A Prospective, Double-Blinded, Monocentric Study of the XPERT(c) Bladder Cancer Monitor and Narrow Band Imaging(c) Cystoscopy. Cancers (Basel), 2022. 14.
https://www.ncbi.nlm.nih.gov/pubmed/35158886
120.Valenberg, F., et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol, 2019. 75: 853.
https://www.ncbi.nlm.nih.gov/pubmed/30553612
121.Valenberg, F., et al. Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with Haematuria. Eur Urol Oncol, 2021. 4: 93.
https://www.ncbi.nlm.nih.gov/pubmed/33004290
122.Dudderidge, T., et al. A Novel, non-invasive Test Enabling Bladder Cancer Detection in Urine Sediment of Patients Presenting with Haematuria-A Prospective Multicentre Performance Evaluation of ADXBLADDER. Eur Urol Oncol, 2020. 3: 42.
https://www.ncbi.nlm.nih.gov/pubmed/31307961
123.Roupret, M., et al. Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Nonmuscle Invasive Bladder Cancer Followup: A Blinded, Prospective Cohort, Multicenter European Study. J Urol, 2020. 204: 685.
https://www.ncbi.nlm.nih.gov/pubmed/32314931
124.van der Aa, M.N., et al. Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [CEFUB]). Eur Urol, 2009. 55: 659.
https://www.ncbi.nlm.nih.gov/pubmed/18501499
125.Roupret, M., et al. A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. BJU Int, 2008. 101: 1448.
https://www.ncbi.nlm.nih.gov/pubmed/18325051
126.Todenhofer, T., et al. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer. BMC Cancer, 2015. 15: 155.
https://www.ncbi.nlm.nih.gov/pubmed/25884545
127.Grossman, H.B., et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA, 2005. 293: 810.
https://www.ncbi.nlm.nih.gov/pubmed/15713770
128.Kim, P.H., et al. Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy. BJU Int, 2014. 114: 354.
https://www.ncbi.nlm.nih.gov/pubmed/24128299
129.Palou, J., et al. Management of Patients with Normal Cystoscopy but Positive Cytology or Urine Markers. Eur Urol Oncol, 2020. 3: 548.
https://www.ncbi.nlm.nih.gov/pubmed/31331861
130.Beukers, W., et al. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study. J Urol, 2017. 197: 1410.
https://www.ncbi.nlm.nih.gov/pubmed/28049011
131.Critelli, R., et al. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up. Oncotarget, 2016. 7: 67435.
https://www.ncbi.nlm.nih.gov/pubmed/27611947
132.Starke, N., et al. Long-term outcomes in a high-risk bladder cancer screening cohort. BJU Int, 2016. 117: 611.
https://www.ncbi.nlm.nih.gov/pubmed/25891519
133.Roobol, M.J., et al. Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project). Urol Oncol, 2010. 28: 686.
https://www.ncbi.nlm.nih.gov/pubmed/21062653
134.Shang, D., et al. Diagnostic value comparison of CellDetect, fluorescent in situ hybridization (FISH), and cytology in urothelial carcinoma. Cancer Cell Int, 2021. 21: 465.
https://www.ncbi.nlm.nih.gov/pubmed/34488763
135.Kurth, K.H., et al. Current methods of assessing and treating carcinoma in situ of the bladder with or without involvement of the prostatic urethra. Int J Urol, 1995. 2 Suppl 2: 8.
https://www.ncbi.nlm.nih.gov/pubmed/7553309
136.Krajewski, W., et al. How different cystoscopy methods influence patient sexual satisfaction, anxiety, and depression levels: a randomized prospective trial. Qual Life Res, 2017. 26: 625.
https://www.ncbi.nlm.nih.gov/pubmed/28050795
137.Aaronson, D.S., et al. Meta-analysis: does lidocaine gel before flexible cystoscopy provide pain relief? BJU Int, 2009. 104: 506.
https://www.ncbi.nlm.nih.gov/pubmed/19239453
138.Berjaoui, M.B., et al. A Prospective Randomized Controlled Trial of Irrigation “Bag Squeeze” to Manage Pain for Patients Undergoing Flexible Cystoscopy. J Urol, 2020. 204: 1012.
https://www.ncbi.nlm.nih.gov/pubmed/32396409
139.Gunendran, T., et al. Does increasing hydrostatic pressure (“bag squeeze”) during flexible cystoscopy improve patient comfort: a randomized, controlled study. Urology, 2008. 72: 255.
https://www.ncbi.nlm.nih.gov/pubmed/18554699
140.Suarez-Ibarrola, R., et al. Surgical checklist impact on recurrence-free survival of patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumour. BJU Int, 2019. 123: 646.
https://www.ncbi.nlm.nih.gov/pubmed/30248235
141.Teoh, J.Y., et al. An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting. Eur Urol, 2020. 78: 546.
https://www.ncbi.nlm.nih.gov/pubmed/32389447
142.Anderson, C., et al. A 10-Item Checklist Improves Reporting of Critical Procedural Elements during Transurethral Resection of Bladder Tumor. J Urol, 2016. 196: 1014.
https://www.ncbi.nlm.nih.gov/pubmed/27044571
143.Mariappan, P., et al. Predicting Grade and Stage at Cystoscopy in Newly Presenting Bladder Cancers-a Prospective Double-Blind Clinical Study. Urology, 2017. 109: 134.
https://www.ncbi.nlm.nih.gov/pubmed/28818537
144.Brausi, M., et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol, 2002. 41: 523.
https://www.ncbi.nlm.nih.gov/pubmed/12074794
145.Richterstetter, M., et al. The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. BJU Int, 2012. 110: E76.
https://www.ncbi.nlm.nih.gov/pubmed/22313727
146.Chai, Y.-M.e.a. The efficacy and safety of thulium laser resection of bladder tumor versus standard transurethral resection in patients with non muscle-invasive bladder cancer: a systematic review and meta-analysis. Journal of Men’s Health, 2021.
https://oss.jomh.org/files/article/20210409-228/pdf/32-42%20JOMH2021010601.pdf
147.Yanagisawa, T., et al. En Bloc Resection for Bladder Tumors: An Updated Systematic Review and Meta-Analysis of Its Differential Effect on Safety, Recurrence and Histopathology. J Urol, 2022. 207: 754.
https://www.ncbi.nlm.nih.gov/pubmed/35060770
148.Kramer, M.W., et al. En bloc resection of urothelium carcinoma of the bladder (EBRUC): a European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor. World J Urol, 2015. 33: 1937.
https://www.ncbi.nlm.nih.gov/pubmed/25910478
149.Hurle, R., et al. “En Bloc” Resection of Nonmuscle Invasive Bladder Cancer: A Prospective Single-center Study. Urology, 2016. 90: 126.
https://www.ncbi.nlm.nih.gov/pubmed/26776561
150.Migliari, R., et al. Thulium Laser Endoscopic En Bloc Enucleation of Nonmuscle-Invasive Bladder Cancer. J Endourol, 2015. 29: 1258.
https://www.ncbi.nlm.nih.gov/pubmed/26102556
151.Zhang, X.R., et al. Two Micrometer Continuous-Wave Thulium Laser Treating Primary Non-Muscle-Invasive Bladder Cancer: Is It Feasible? A Randomized Prospective Study. Photomed Laser Surg, 2015. 33: 517.
https://www.ncbi.nlm.nih.gov/pubmed/26397029
152.Hashem, A., et al. Holmium Laser En-bloc Resection Versus Conventional Transurethral Resection of Bladder Tumors for Treatment of Non-muscle-invasive Bladder Cancer: A Randomized Clinical Trial. Eur Urol Focus, 2021. 7: 1035.
https://www.ncbi.nlm.nih.gov/pubmed/33386289
153.Fan, J., et al. Green-light laser en bloc resection versus conventional transurethral resection for initial non-muscle-invasive bladder cancer: A randomized controlled trial. Int J Urol, 2021. 28: 855.
https://www.ncbi.nlm.nih.gov/pubmed/34013615
154.Badawy, A., et al. Thulium laser en bloc resection versus conventional transurethral resection of urinary bladder tumor: A comparative prospective study. Urol Ann, 2023. 15: 88.
https://www.ncbi.nlm.nih.gov/pubmed/37006212
155.Gallioli, A., et al. En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Single-center Prospective Randomized Noninferiority Trial. Eur Urol Oncol, 2022. 5: 440.
https://www.ncbi.nlm.nih.gov/pubmed/35618567
156.D’Andrea, D., et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol, 2023. 6: 508.
https://www.ncbi.nlm.nih.gov/pubmed/37543464
157.Li, Z., et al. Systematic review and meta-analysis of randomized controlled trials of perioperative outcomes and prognosis of transurethral en-bloc resection vs. conventional transurethral resection for non-muscle-invasive bladder cancer. Int J Surg, 2022. 104: 106777.
https://www.ncbi.nlm.nih.gov/pubmed/35850465
158.Teoh, J.Y., et al. En-bloc resection of bladder tumour as primary treatment for patients with non-muscle-invasive bladder cancer: routine implementation in a multi-centre setting. World J Urol, 2021. 39: 3353.
https://www.ncbi.nlm.nih.gov/pubmed/33774705
159.Mariappan, P., et al. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol, 2010. 57: 843.
https://www.ncbi.nlm.nih.gov/pubmed/19524354
160.Taoka, R., et al. Use of surgical checklist during transurethral resection increases detrusor muscle collection rate and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer. Int J Urol, 2021. 28: 727.
https://www.ncbi.nlm.nih.gov/pubmed/33742465
161.Mariappan, P., et al. Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland’s Quality Performance Indicators Programme. Eur Urol, 2020. 78: 520.
https://www.ncbi.nlm.nih.gov/pubmed/32690321
162.Del Giudice, F., et al. Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators. BJU Int, 2023. 131: 712.
https://www.ncbi.nlm.nih.gov/pubmed/36251366
163.Mariappan, P., et al. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int, 2012. 109: 1666.
https://www.ncbi.nlm.nih.gov/pubmed/22044434
164.Neumann, E., et al. Transurethral Resection of Bladder Tumors: Next-generation Virtual Reality Training for Surgeons. Eur Urol Focus, 2019. 5: 906.
https://www.ncbi.nlm.nih.gov/pubmed/29802051
165.Bebane, S., et al. Perioperative outcomes of transurethral resection for t1 bladder tumors: quality evaluation based on patient, tumor and surgeon criteria. World J Urol, 2021. 39: 4159.
https://www.ncbi.nlm.nih.gov/pubmed/34160681
166.Jancke, G., et al. Impact of surgical experience on recurrence and progression after transurethral resection of bladder tumour in non-muscle-invasive bladder cancer. Scand J Urol, 2014. 48: 276.
https://www.ncbi.nlm.nih.gov/pubmed/24286506
167.Wettstein, M.S., et al. Association between surgical case volume and survival in T1 bladder cancer: A plea for regionalization of care? Canadian Urological Association Journal, 2020. 14: E394.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492039/
168.Mao, X., et al. Outcomes and Complications of Bipolar vs. Monopolar Energy for Transurethral Resection of Bladder Tumors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Surg, 2021. 8: 583806.
https://www.ncbi.nlm.nih.gov/pubmed/34150834
169.Tzelves, L., et al. Does bipolar energy provide any advantage over monopolar surgery in transurethral resection of non-muscle invasive bladder tumors? A systematic review and meta-analysis. World J Urol, 2021. 39: 1093.
https://www.ncbi.nlm.nih.gov/pubmed/32591900
170.Xie, K., et al. Bipolar versus monopolar transurethral resection of non-muscle-invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trials. World J Urol, 2021. 39: 1177.
https://www.ncbi.nlm.nih.gov/pubmed/32462303
171.Picozzi, S.C., et al. Is it oncologically safe performing simultaneous transurethral resection of the bladder and prostate? A meta-analysis on 1,234 patients. Int Urol Nephrol, 2012. 44: 1325.
https://www.ncbi.nlm.nih.gov/pubmed/22710969
172.Tsivian, A., et al. Simultaneous transurethral resection of bladder tumor and benign prostatic hyperplasia: hazardous or a safe timesaver? J Urol, 2003. 170: 2241.
https://www.ncbi.nlm.nih.gov/pubmed/14634388
173.Sari Motlagh, R., et al. The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int, 2021. 127: 143.
https://www.ncbi.nlm.nih.gov/pubmed/32564458
174.Laukhtina, E., et al. Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate. BJU Int, 2023. 131: 571.
https://www.ncbi.nlm.nih.gov/pubmed/36134575
175.van der Meijden, A., et al. Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. Eur Urol, 1999. 35: 267.
https://www.ncbi.nlm.nih.gov/pubmed/10419345
176.Hara, T., et al. Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases. Int J Urol, 2009. 16: 293.
https://www.ncbi.nlm.nih.gov/pubmed/19207607
177.Palou, J., et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin. Eur Urol, 2012. 62: 118.
https://www.ncbi.nlm.nih.gov/pubmed/22101115
178.Mungan, M.U., et al. Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder. Eur Urol, 2005. 48: 760.
https://www.ncbi.nlm.nih.gov/pubmed/16005563
179.Brant, A., et al. Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer. World J Urol, 2019. 37: 2683.
https://www.ncbi.nlm.nih.gov/pubmed/30850856
180.Huguet, J., et al. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol, 2005. 48: 53.
https://www.ncbi.nlm.nih.gov/pubmed/15967252
181.Kausch, I., et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol, 2010. 57: 595.
https://www.ncbi.nlm.nih.gov/pubmed/20004052
182.Mowatt, G., et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. Int J Technol Assess Health Care, 2011. 27: 3.
https://www.ncbi.nlm.nih.gov/pubmed/21262078
183.Neuzillet, Y., et al. Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology. Urol Oncol, 2014. 32: 1135.
https://www.ncbi.nlm.nih.gov/pubmed/25023786
184.Draga, R.O., et al. Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guerin immunotherapy and mitomycin C intravesical therapy. Eur Urol, 2010. 57: 655.
https://www.ncbi.nlm.nih.gov/pubmed/19819064
185.Ray, E.R., et al. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guerin. BJU Int, 2010. 105: 789.
https://www.ncbi.nlm.nih.gov/pubmed/19832725
186.Chou, R., et al. Comparative Effectiveness of Fluorescent Versus White Light Cystoscopy for Initial Diagnosis or Surveillance of Bladder Cancer on Clinical Outcomes: Systematic Review and Meta-Analysis. J Urol, 2017. 197: 548.
https://www.ncbi.nlm.nih.gov/pubmed/27780784
187.Veeratterapillay, R., et al. Time to Turn on the Blue Lights: A Systematic Review and Meta-analysis of Photodynamic Diagnosis for Bladder Cancer. Eur Urol Open Sci, 2021. 31: 17.
https://www.ncbi.nlm.nih.gov/pubmed/34467237
188.Maisch, P., et al. Blue vs white light for transurethral resection of non-muscle-invasive bladder cancer: an abridged Cochrane Review. BJU Int, 2022. 130: 730.
https://www.ncbi.nlm.nih.gov/pubmed/35238145
189.Zhao, H., et al. Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials. Photodiagnosis Photodyn Ther, 2023. 41: 103220.
https://www.ncbi.nlm.nih.gov/pubmed/36462704
190.Heer, R., et al. A Randomized Trial of PHOTOdynamic Surgery in Non–Muscle-Invasive Bladder Cancer. NEJM Evidence, 2022. 1.
https://evidence.nejm.org/doi/10.1056/EVIDoa2200092
191.Zheng, C., et al. Narrow band imaging diagnosis of bladder cancer: systematic review and meta-analysis. BJU Int, 2012. 110: E680.
https://www.ncbi.nlm.nih.gov/pubmed/22985502
192.Drejer, D., et al. Clinical relevance of narrow-band imaging in flexible cystoscopy: the DaBlaCa-7 study. Scand J Urol, 2017. 51: 120.
https://www.ncbi.nlm.nih.gov/pubmed/28266904
193.Ye, Z., et al. A comparison of NBI and WLI cystoscopy in detecting non-muscle-invasive bladder cancer: A prospective, randomized and multi-center study. Sci Rep, 2015. 5: 10905.
https://www.ncbi.nlm.nih.gov/pubmed/26046790
194.Kim, S.B., et al. Detection and recurrence rate of transurethral resection of bladder tumors by narrow-band imaging: Prospective, randomized comparison with white light cystoscopy. Investig Clin Urol, 2018. 59: 98.
https://www.ncbi.nlm.nih.gov/pubmed/29520385
195.Naito, S., et al. The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) Versus Conventional White Light Imaging-Assisted TURBT in Primary Non-Muscle-invasive Bladder Cancer Patients: Trial Protocol and 1-year Results. Eur Urol, 2016. 70: 506.
https://www.ncbi.nlm.nih.gov/pubmed/27117749
196.Russo, G.I., et al. Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis. Cancers (Basel), 2021. 13.
https://www.ncbi.nlm.nih.gov/pubmed/34503188
197.Li, H., et al. Novel Visualization Methods Assisted Transurethral Resection for Bladder Cancer: An Updated Survival-Based Systematic Review and Meta-Analysis. Front Oncol, 2021. 11: 644341.
https://www.ncbi.nlm.nih.gov/pubmed/34327134
198.Sari Motlagh, R., et al. Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized trials. BJU Int, 2021. 128: 280.
https://www.ncbi.nlm.nih.gov/pubmed/33683778
199.Howard, J.M., et al. Enhanced Endoscopy with IMAGE1 S CHROMA Improves Detection of Nonmuscle Invasive Bladder Cancer During Transurethral Resection. J Endourol, 2021. 35: 647.
https://www.ncbi.nlm.nih.gov/pubmed/33176470
200.Mulawkar, P., et al. Evaluation of Spectra A and B Modes in Diagnosis of Suspicious Bladder Lesions. J Endourol, 2021. 35: 1184.
https://www.ncbi.nlm.nih.gov/pubmed/33446044
201.de la Rosette, J., et al. Conventional white light imaging-assisted transurethral resection of bladder tumour (TURBT) versus IMAGE1S-assisted TURBT in non-muscle-invasive bladder cancer patients: trial protocol and 18 months results. World J Urol, 2022. 40: 727.
https://www.ncbi.nlm.nih.gov/pubmed/34741631
202.Liem, E., et al. Validation of Confocal Laser Endomicroscopy Features of Bladder Cancer: The Next Step Towards Real-time Histologic Grading. Eur Urol Focus, 2020. 6: 81.
https://www.ncbi.nlm.nih.gov/pubmed/30033066
203.Cumberbatch, M.G.K., et al. Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. Eur Urol, 2018. 73: 925.
https://www.ncbi.nlm.nih.gov/pubmed/29523366
204.Naselli, A., et al. Role of Restaging Transurethral Resection for T1 Non-muscle invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus, 2018. 4: 558.
https://www.ncbi.nlm.nih.gov/pubmed/28753839
205.Elsawy, A.A., et al. Diagnostic performance and predictive capacity of early urine cytology after transurethral resection of nonmuscle invasive bladder cancer: A prospective study. Urol Oncol, 2020. 38: 935 e1.
https://www.ncbi.nlm.nih.gov/pubmed/32654947
206.Elsawy, A.A., et al. Can repeat biopsy be skipped after initial complete resection of T1 bladder cancer? The role of a novel urinary mRNA biomarker. Urol Oncol, 2021. 39: 437 e11.
https://www.ncbi.nlm.nih.gov/pubmed/33785220
207.Grimm, M.O., et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol, 2003. 170: 433.
https://www.ncbi.nlm.nih.gov/pubmed/12853793
208.Eroglu, A., et al. The prognostic value of routine second transurethral resection in patients with newly diagnosed stage pT1 non-muscle-invasive bladder cancer: results from randomized 10-year extension trial. Int J Clin Oncol, 2020. 25: 698.
https://www.ncbi.nlm.nih.gov/pubmed/31760524
209.Lee, K., et al. Evaluating the efficacy of secondary transurethral resection of the bladder for high-grade Ta tumors. Investig Clin Urol, 2022. 63: 14.
https://www.ncbi.nlm.nih.gov/pubmed/34983118
210.Gordon, P.C., et al. Long-term Outcomes from Re-resection for High-risk Non-muscle-invasive Bladder Cancer: A Potential to Rationalize Use. Eur Urol Focus, 2019. 5: 650.
https://www.ncbi.nlm.nih.gov/pubmed/29089252
211.Hashine, K., et al. Results of second transurethral resection for high-grade T1 bladder cancer. Urol Ann, 2016. 8: 10.
https://www.ncbi.nlm.nih.gov/pubmed/26834394
212.Dalbagni, G., et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol, 2009. 56: 903.
https://www.ncbi.nlm.nih.gov/pubmed/19632765
213.Bishr, M., et al. Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer. Can Urol Assoc J, 2014. 8: E306.
https://www.ncbi.nlm.nih.gov/pubmed/24940455
214.Palou, J., et al. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. World J Urol, 2018. 36: 1621.
https://www.ncbi.nlm.nih.gov/pubmed/29721611
215.Gontero, P., et al. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guerin. BJU Int, 2016. 118: 44.
https://www.ncbi.nlm.nih.gov/pubmed/26469362
216.Hensley, P.J., et al. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guerin Therapy Outcomes. Eur Urol Oncol, 2022. 5: 347.
https://www.ncbi.nlm.nih.gov/pubmed/33935020
217.Baltaci, S., et al. Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette-Guerin. BJU Int, 2015. 116: 721.
https://www.ncbi.nlm.nih.gov/pubmed/25715815
218.Paner, G.P., et al. Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances. Adv Anat Pathol, 2017. 24: 113.
https://www.ncbi.nlm.nih.gov/pubmed/28398951
219.ICCR. Urinary Tract Carcinoma Biopsy and Transurethral Resection Specimen (TNM8). 2019. 2022.
http://www.iccr-cancer.org/datasets/published-datasets/urinary-male-genital/ut-biopsy-and-tr
220.Mostafid, H., et al. Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. Eur Urol Oncol, 2021. 4: 12.
https://www.ncbi.nlm.nih.gov/pubmed/32684515
221.Sylvester, R.J., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol, 2006. 49: 466.
https://www.ncbi.nlm.nih.gov/pubmed/16442208
222.Lammers, R.J., et al. Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation. World J Urol, 2016. 34: 173.
https://www.ncbi.nlm.nih.gov/pubmed/26025189
223.Fernandez-Gomez, J., et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol, 2009. 182: 2195.
https://www.ncbi.nlm.nih.gov/pubmed/19758621
224.Fernandez-Gomez, J., et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables. Eur Urol, 2011. 60: 423.
https://www.ncbi.nlm.nih.gov/pubmed/21621906
225.van Rhijn, B.W., et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol, 2010. 58: 433.
https://www.ncbi.nlm.nih.gov/pubmed/20646825
226.Cambier, S., et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin. Eur Urol, 2016. 69: 60.
https://www.ncbi.nlm.nih.gov/pubmed/26210894
227.Sylvester, R.J., et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol, 2021. 79: 480.
https://www.ncbi.nlm.nih.gov/pubmed/33419683
228.Gontero, P., et al. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients. Eur Urol, 2015. 67: 74.
https://www.ncbi.nlm.nih.gov/pubmed/25043942
229.Voskuilen, C.S., et al. Urothelial Carcinoma in Bladder Diverticula: A Multicenter Analysis of Characteristics and Clinical Outcomes. Eur Urol Focus, 2020. 6: 1226.
https://www.ncbi.nlm.nih.gov/pubmed/30559065
230.Palou, J., et al. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors. Urology, 2009. 73: 1313.
https://www.ncbi.nlm.nih.gov/pubmed/19362341
231.Alkhateeb, S.S., et al. Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guerin. Urol Ann, 2011. 3: 119.
https://www.ncbi.nlm.nih.gov/pubmed/21976923
232.Lamm, D.L. Carcinoma in situ. Urol Clin North Am, 1992. 19: 499.
https://www.ncbi.nlm.nih.gov/pubmed/1636234
233.Losa, A., et al. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol, 2000. 163: 68.
https://www.ncbi.nlm.nih.gov/pubmed/10604316
234.Griffiths, T.R., et al. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol, 2002. 167: 2408.
https://www.ncbi.nlm.nih.gov/pubmed/11992047
235.Takenaka, A., et al. Clinical outcomes of bacillus Calmette-Guerin instillation therapy for carcinoma in situ of urinary bladder. Int J Urol, 2008. 15: 309.
https://www.ncbi.nlm.nih.gov/pubmed/18380817
236.Solsona, E., et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol, 2000. 164: 685.
https://www.ncbi.nlm.nih.gov/pubmed/10953125
237.van Gils-Gielen, R.J., et al. Risk factors in carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Urology, 1995. 45: 581.
https://www.ncbi.nlm.nih.gov/pubmed/7716838
238.Lobo, N., et al. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin. Eur Urol Oncol, 2022. 5: 84.
https://www.ncbi.nlm.nih.gov/pubmed/34920986
239.Lammers, R.J., et al. Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. Eur Urol, 2011. 60: 713.
https://www.ncbi.nlm.nih.gov/pubmed/21794974
240.Rink, M., et al. Smoking reduces the efficacy of intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer. Eur Urol, 2012. 62: 1204.
https://www.ncbi.nlm.nih.gov/pubmed/22980442
241.Slusarczyk, A., et al. The impact of smoking on recurrence and progression of non-muscle invasive bladder cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol, 2023. 149: 2673.
https://www.ncbi.nlm.nih.gov/pubmed/36404390
242.Ho, C.-H., et al. Association between Smoking and Overall and Specific Mortality in Patients with Bladder Cancer: A Population-based Study. Bladder Cancer, 2022. 8: 129.
http://www.iospress.nl/journal/bladder-cancer/
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed23&NEWS=N&AN=638216135
243.Rink, M., et al. Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. J Urol, 2012. 188: 2120.
https://www.ncbi.nlm.nih.gov/pubmed/23083868
244.Crivelli, J.J., et al. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol, 2014. 65: 742.
https://www.ncbi.nlm.nih.gov/pubmed/23810104
245.Muller, J., et al. Trends in the risk of second primary cancer among bladder cancer survivors: a population-based cohort of 10 047 patients. BJU Int, 2016. 118: 53.
https://www.ncbi.nlm.nih.gov/pubmed/26469096
246.Xu, Y., et al. Comparing the treatment outcomes of potassium-titanyl-phosphate laser vaporization and transurethral electroresection for primary nonmuscle-invasive bladder cancer: A prospective, randomized study. Lasers Surg Med, 2015. 47: 306.
https://www.ncbi.nlm.nih.gov/pubmed/25864416
247.Planelles Gomez, J., et al. Holmium YAG Photocoagulation: Safe and Economical Alternative to Transurethral Resection in Small Nonmuscle-Invasive Bladder Tumors. J Endourol, 2017. 31: 674.
https://www.ncbi.nlm.nih.gov/pubmed/28462594
248.Pedersen, G.L., et al. Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A Prospective Randomized Noninferiority Clinical Trial. Eur Urol, 2023. 83: 125.
https://www.ncbi.nlm.nih.gov/pubmed/36058804
249.Holmang, S., et al. Recurrence and progression in low grade papillary urothelial tumors. J Urol, 1999. 162: 702.
https://www.ncbi.nlm.nih.gov/pubmed/10458347
250.Holmang, S., et al. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol, 2002. 167: 1634.
https://www.ncbi.nlm.nih.gov/pubmed/11912378
251.Mariappan, P., et al. Pattern of recurrence changes in noninvasive bladder tumors observed during 2 decades. J Urol, 2007. 177: 867.
https://www.ncbi.nlm.nih.gov/pubmed/17296362
252.Holmang, S., et al. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol, 2001. 165: 1124.
https://www.ncbi.nlm.nih.gov/pubmed/11257652
253.Mariappan, P., et al. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol, 2005. 173: 1108.
https://www.ncbi.nlm.nih.gov/pubmed/15758711
254.Millan-Rodriguez, F. Millan-Rodriguez F, et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 2000;164(3 Pt 1):680-684. J Urol, 2000.
https://pubmed.ncbi.nlm.nih.gov/10954628/
255.Soloway, M.S., et al. Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol, 2003. 170: 438.
https://www.ncbi.nlm.nih.gov/pubmed/12853794
256.Miyake, M., et al. Active surveillance for nonmuscle invasive bladder cancer. Investig Clin Urol, 2016. 57 Suppl 1: S4.
https://www.ncbi.nlm.nih.gov/pubmed/27326406
257.Marcq, G., et al. Active surveillance for non-muscle invasive bladder cancer. Transl Androl Urol, 2019. 8: 54.
https://www.ncbi.nlm.nih.gov/pubmed/30976569
258.Contieri, R., et al. Long-term Follow-up and Factors Associated with Active Surveillance Failure for Patients with Non-muscle-invasive Bladder Cancer: The Bladder Cancer Italian Active Surveillance (BIAS) Experience. Eur Urol Oncol, 2022. 5: 251.
https://www.ncbi.nlm.nih.gov/pubmed/34059485
259.Hurle, R., et al. Active surveillance for low-risk non-muscle-invasive bladder cancer: mid-term results from the Bladder cancer Italian Active Surveillance (BIAS) project. BJU Int, 2016. 118: 935.
https://www.ncbi.nlm.nih.gov/pubmed/27207387
260.Tan, W.S., et al. International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance. J Urol, 2023. 210: 763.
https://www.ncbi.nlm.nih.gov/pubmed/37535836
261.Li, M., et al. Continuous bladder irrigation after transurethral resection of non-muscle invasive bladder cancer for prevention of tumour recurrence: a systematic review. ANZ J Surg, 2021. 91: 2592.
https://www.ncbi.nlm.nih.gov/pubmed/33890701
262.Mahran, A., et al. Bladder irrigation after transurethral resection of superficial bladder cancer: a systematic review of the literature. Can J Urol, 2018. 25: 9579.
https://www.ncbi.nlm.nih.gov/pubmed/30553282
263.Zhou, Z., et al. Meta-analysis of efficacy and safety of continuous saline bladder irrigation compared with intravesical chemotherapy after transurethral resection of bladder tumors. World J Urol, 2019. 37: 1075.
https://www.ncbi.nlm.nih.gov/pubmed/30612154
264.Soloway, M.S., et al. Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer, 1980. 46: 1158.
https://www.ncbi.nlm.nih.gov/pubmed/7214299
265.Pan, J.S., et al. Inhibition of implantation of murine bladder tumor by thiotepa in cauterized bladder. J Urol, 1989. 142: 1589.
https://www.ncbi.nlm.nih.gov/pubmed/2511340
266.Brocks, C.P., et al. Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer. J Urol, 2005. 174: 1115.
https://www.ncbi.nlm.nih.gov/pubmed/16094076
267.Oosterlinck, W., et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol, 1993. 149: 749.
https://www.ncbi.nlm.nih.gov/pubmed/8455236
268.Sylvester, R.J., et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? Eur Urol, 2016. 69: 231.
https://www.ncbi.nlm.nih.gov/pubmed/26091833
269.Sylvester, R.J., et al. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol, 2004. 171: 2186.
https://www.ncbi.nlm.nih.gov/pubmed/15126782
270.Abern, M.R., et al. Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. J Natl Compr Canc Netw, 2013. 11: 477.
https://www.ncbi.nlm.nih.gov/pubmed/23584348
271.Perlis, N., et al. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. Eur Urol, 2013. 64: 421.
https://www.ncbi.nlm.nih.gov/pubmed/23830475
272.Messing, E.M., et al. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA, 2018. 319: 1880.
https://www.ncbi.nlm.nih.gov/pubmed/29801011
273.Bohle, A., et al. Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. Eur Urol, 2009. 56: 495.
https://www.ncbi.nlm.nih.gov/pubmed/19560257
274.Pode, D., et al. The mechanism of human bladder tumor implantation in an in vitro model. J Urol, 1986. 136: 482.
https://www.ncbi.nlm.nih.gov/pubmed/3525861
275.Bohle, A., et al. Inhibition of bladder carcinoma cell adhesion by oligopeptide combinations in vitro and in vivo. J Urol, 2002. 167: 357.
https://www.ncbi.nlm.nih.gov/pubmed/11743356
276.Gofrit, O.N., et al. The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Guerin immunotherapy. Urol Oncol, 2009. 27: 258.
https://www.ncbi.nlm.nih.gov/pubmed/18440839
277.Karsh, L., et al. Double-Blind, Randomized, Placebo-controlled Studies Evaluating Apaziquone (E09, Qapzola) Intravesical Instillation Post Transurethral Resection of Bladder Tumors for the Treatment of Low-risk Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2018. 4: 293.
https://www.ncbi.nlm.nih.gov/pubmed/30112440
278.Oddens, J.R., et al. One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe? Eur Urol, 2004. 46: 336.
https://www.ncbi.nlm.nih.gov/pubmed/15306104
279.Elmamoun, M.H., et al. Destruction of the bladder by single dose Mitomycin C for low-stage transitional cell carcinoma (TCC)--avoidance, recognition, management and consent. BJU Int, 2014. 113: E34.
https://www.ncbi.nlm.nih.gov/pubmed/24053461
280.Dunsmore, J., et al. What influences adherence to guidance for postoperative instillation of intravesical chemotherapy to patients with bladder cancer? BJU Int, 2021. 128: 225.
https://www.ncbi.nlm.nih.gov/pubmed/33450116
281.Tolley, D.A., et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol, 1996. 155: 1233.
https://www.ncbi.nlm.nih.gov/pubmed/8632538
282.Huncharek, M., et al. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res, 2001. 21: 765.
https://www.ncbi.nlm.nih.gov/pubmed/11299841
283.Bohle, A., et al. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology, 2004. 63: 682.
https://www.ncbi.nlm.nih.gov/pubmed/15072879
284.Sylvester, R.J., et al. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol, 2002. 168: 1964.
https://www.ncbi.nlm.nih.gov/pubmed/12394686
285.Malmstrom, P.U., et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol, 2009. 56: 247.
https://www.ncbi.nlm.nih.gov/pubmed/19409692
286.Sylvester, R.J., et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol, 2010. 57: 766.
https://www.ncbi.nlm.nih.gov/pubmed/20034729
287.Shang, P.F., et al. Intravesical Bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev, 2011: CD006885.
https://www.ncbi.nlm.nih.gov/pubmed/21563157
288.Bosschieter, J., et al. Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients. Eur Urol, 2018. 73: 226.
https://www.ncbi.nlm.nih.gov/pubmed/28705539
289.Bouffioux, C., et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol, 1995. 153: 934.
https://www.ncbi.nlm.nih.gov/pubmed/7853578
290.Kaasinen, E., et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol, 2002. 42: 167.
https://www.ncbi.nlm.nih.gov/pubmed/12160589
291.Sylvester, R.J., et al. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials. Eur Urol, 2008. 53: 709.
https://www.ncbi.nlm.nih.gov/pubmed/18207317
292.Bosschieter, J., et al. An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non-muscle-invasive bladder cancer irrespective of prognostic risk groups. Urol Oncol, 2018. 36: 400 e7.
https://www.ncbi.nlm.nih.gov/pubmed/30064935
293.Elsawy, A.A., et al. The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non-muscle-invasive bladder cancer: A preliminary results of randomized controlled trial. Urol Oncol, 2019. 37: 179 e9.
https://www.ncbi.nlm.nih.gov/pubmed/30448030
294.Tabayoyong, W.B., et al. Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer. Eur Urol Focus, 2018. 4: 512.
https://www.ncbi.nlm.nih.gov/pubmed/30190111
295.Au, J.L., et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst, 2001. 93: 597.
https://www.ncbi.nlm.nih.gov/pubmed/11309436
296.Miyata, Y., et al. Intravesical mitomycin C (MMC) and MMC + cytosine arabinoside for non-muscle-invasive bladder cancer: a randomised clinical trial. BJU Int, 2022. 129: 534.
https://www.ncbi.nlm.nih.gov/pubmed/34383381
297.Myers, A.L., et al. Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration. Drugs R D, 2017. 17: 297.
https://www.ncbi.nlm.nih.gov/pubmed/28470465
298.Giesbers, A.A., et al. Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times. Br J Urol, 1989. 63: 176.
https://www.ncbi.nlm.nih.gov/pubmed/2495144
299.Kuroda, M., et al. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml. Eur Urol, 2004. 45: 600.
https://www.ncbi.nlm.nih.gov/pubmed/15082202
300.Zhao, H., et al. Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Front Surg, 2021. 8: 775527.
https://www.ncbi.nlm.nih.gov/pubmed/34888347
301.Arends, T.J., et al. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. J Urol, 2014. 192: 708.
https://www.ncbi.nlm.nih.gov/pubmed/24704017
302.Arends, T.J., et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol, 2016. 69: 1046.
https://www.ncbi.nlm.nih.gov/pubmed/26803476
303.Tan, W.S., et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol, 2023. 83: 497.
https://www.ncbi.nlm.nih.gov/pubmed/35999119
304.Angulo, J.C., et al. Hyperthermic Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial. Eur Urol Oncol, 2023. 6: 58.
https://www.ncbi.nlm.nih.gov/pubmed/36435738
305.Guerrero-Ramos, F., et al. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial. World J Urol, 2022. 40: 999.
https://www.ncbi.nlm.nih.gov/pubmed/35037963
306.Di Stasi, S.M., et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol, 2006. 7: 43.
https://www.ncbi.nlm.nih.gov/pubmed/16389183
307.Shelley, M.D., et al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int, 2001. 88: 209.
https://www.ncbi.nlm.nih.gov/pubmed/11488731
308.Han, R.F., et al. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology, 2006. 67: 1216.
https://www.ncbi.nlm.nih.gov/pubmed/16765182
309.Shelley, M.D., et al. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int, 2004. 93: 485.
https://www.ncbi.nlm.nih.gov/pubmed/15008714
310.Bohle, A., et al. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol, 2003. 169: 90.
https://www.ncbi.nlm.nih.gov/pubmed/12478111
311.Duchek, M., et al. Bacillus Calmette-Guerin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Eur Urol, 2010. 57: 25.
https://www.ncbi.nlm.nih.gov/pubmed/19819617
312.Jarvinen, R., et al. Long-term efficacy of maintenance bacillus Calmette-Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol, 2009. 56: 260.
https://www.ncbi.nlm.nih.gov/pubmed/19395154
313.Schmidt, S., et al. Intravesical Bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev, 2020. 1: CD011935.
https://www.ncbi.nlm.nih.gov/pubmed/31912907
314.Huncharek, M., et al. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. Am J Clin Oncol, 2004. 27: 522.
https://www.ncbi.nlm.nih.gov/pubmed/15596924
315.Oddens, J.R., et al. The effect of age on the efficacy of maintenance bacillus Calmette-Guerin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Eur Urol, 2014. 66: 694.
https://www.ncbi.nlm.nih.gov/pubmed/24948466
316.Miyake, M., et al. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guerin after radical nephroureterectomy for upper urinary tract urothelial carcinoma. BJU Int, 2018. 121: 764.
https://www.ncbi.nlm.nih.gov/pubmed/29281857
317.Rentsch, C.A., et al. Bacillus Calmette-Guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol, 2014. 66: 677.
https://www.ncbi.nlm.nih.gov/pubmed/24674149
318.Sengiku, A., et al. A prospective comparative study of intravesical bacillus Calmette-Guerin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer. J Urol, 2013. 190: 50.
https://www.ncbi.nlm.nih.gov/pubmed/23376145
319.Boehm, B.E., et al. Efficacy of bacillus Calmette-Guerin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis. J Urol, 2017. 198: 503.
https://www.ncbi.nlm.nih.gov/pubmed/28286068
320.Unda-Urzaiz, M., et al. Safety and efficacy of various strains of bacille Calmette-Guerin in the treatment of bladder tumours in standard clinical practice. Actas Urol Esp (Engl Ed), 2018. 42: 238.
https://www.ncbi.nlm.nih.gov/pubmed/29295749
321.Steinberg, R.L., et al. Bacillus Calmette-Guerin strain may not effect recurrence-free survival when used intravesically with interferon-alpha2b for non-muscle-invasive bladder cancer. Urol Oncol, 2017. 35: 201.
https://www.ncbi.nlm.nih.gov/pubmed/28041998
322.van der Meijden, A.P., et al. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol, 2003. 44: 429.
https://www.ncbi.nlm.nih.gov/pubmed/14499676
323.Larsen, E.S., et al. The epidemiology of bacille Calmette-Guerin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study. BJU Int, 2019. 124: 910.
https://www.ncbi.nlm.nih.gov/pubmed/31054198
324.Brausi, M., et al. Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol, 2014. 65: 69.
https://www.ncbi.nlm.nih.gov/pubmed/23910233
325.Oddens, J.R., et al. Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance bacille Calmette-Guerin: results from European Organisation for Research and Treatment of Cancer Genito-Urinary Group study 30911. BJU Int, 2016. 118: 423.
https://www.ncbi.nlm.nih.gov/pubmed/26945890
326.Danielsson, G., et al. Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer - a follow-up five years after the start of treatment. Scand J Urol, 2018. 52: 377.
https://www.ncbi.nlm.nih.gov/pubmed/30616479
327.Herr, H.W. Intravesical bacillus Calmette-Guerin outcomes in patients with bladder cancer and asymptomatic bacteriuria. J Urol, 2012. 187: 435.
https://www.ncbi.nlm.nih.gov/pubmed/22177154
328.Colombel, M., et al. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol, 2006. 176: 935.
https://www.ncbi.nlm.nih.gov/pubmed/16890660
329.Damiano, R., et al. Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guerin-induced toxicity? BJU Int, 2009. 104: 633.
https://www.ncbi.nlm.nih.gov/pubmed/19298412
330.Numakura, K., et al. Effect of Levofloxacin on the Efficacy and Adverse Events in Intravesical Bacillus Calmette-Guerin Treatment for Bladder Cancer: Results of a Randomized, Prospective, Multicenter Study. Eur Urol Focus, 2022. 8: 1666.
https://www.ncbi.nlm.nih.gov/pubmed/35717522
331.Lamm, D.L., et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol, 1992. 147: 596.
https://www.ncbi.nlm.nih.gov/pubmed/1538436
332.Palou, J., et al. Intravesical bacillus Calmette-Guerin for the treatment of superficial bladder cancer in renal transplant patients. Transplantation, 2003. 76: 1514.
https://www.ncbi.nlm.nih.gov/pubmed/14657696
333.Yossepowitch, O., et al. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. J Urol, 2006. 176: 482.
https://www.ncbi.nlm.nih.gov/pubmed/16813873
334.Roumeguere, T., et al. Bacillus Calmette-Guerin therapy in non-muscle-invasive bladder carcinoma after renal transplantation for end-stage aristolochic acid nephropathy. Transpl Int, 2015. 28: 199.
https://www.ncbi.nlm.nih.gov/pubmed/25377421
335.Jue, J.S., et al. Risk factors, management, and survival of bladder cancer after kidney transplantation. Actas Urol Esp (Engl Ed), 2021. 45: 427.
https://www.ncbi.nlm.nih.gov/pubmed/34147429
336.Rodriguez, F., et al. [Practical guideline for the management of adverse events associated with BCG installations]. Arch Esp Urol, 2008. 61: 591.
https://www.ncbi.nlm.nih.gov/pubmed/18709813
337.Witjes JA, P.J., Soloway M, et al. . Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. Eur Urol Suppl, 2008. 7: 667.
http://www.europeanurology.com/article/S1569-9056(08)00110-3/abstract
338.Palou, J., et al. Intravesical treatment of severe bacillus Calmette-Guerin cystitis. Int Urol Nephrol, 2001. 33: 485.
https://www.ncbi.nlm.nih.gov/pubmed/12230277
339.Falkensammer, C., et al. Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette-Guerin therapy for superficial bladder carcinoma. Urology, 2005. 65: 175.
https://www.ncbi.nlm.nih.gov/pubmed/15667898
340.Tinazzi, E., et al. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int, 2006. 26: 481.
https://www.ncbi.nlm.nih.gov/pubmed/16220289
341.European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. 2019. 2022.
342.Bonkat, G., Bartoletti, R., Bruyere, F., et al. , EAU Guidelines on Urological Infections, in EAU Guidelines Edn. presented at the 38th Annual Congress Milan, E.G. Office, Editor. 2023, EAU Guidelines Office: Arnhem, The Netherlands.
343.Morales, A., et al. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol, 1976. 116: 180.
https://www.ncbi.nlm.nih.gov/pubmed/820877
344.Lamm, D.L., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol, 2000. 163: 1124.
https://www.ncbi.nlm.nih.gov/pubmed/10737480
345.Grimm, M.O., et al. Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial “NIMBUS”. Eur Urol, 2020. 78: 690.
https://www.ncbi.nlm.nih.gov/pubmed/32446864
346.Martinez-Pineiro, L., et al. Maintenance Therapy with 3-monthly Bacillus Calmette-Guerin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013. Eur Urol, 2015. 68: 256.
https://www.ncbi.nlm.nih.gov/pubmed/25794457
347.Oddens, J., et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol, 2013. 63: 462.
https://www.ncbi.nlm.nih.gov/pubmed/23141049
348.Martinez-Pineiro, J.A., et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int, 2002. 89: 671.
https://www.ncbi.nlm.nih.gov/pubmed/11966623
349.Martinez-Pineiro, J.A., et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol, 2005. 174: 1242.
https://www.ncbi.nlm.nih.gov/pubmed/16145378
350.Ojea, A., et al. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol, 2007. 52: 1398.
https://www.ncbi.nlm.nih.gov/pubmed/17485161
351.Choi, S.Y., et al. Low-dose versus standard-dose bacille Calmette-Guerin for non-muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized controlled trials. Investig Clin Urol, 2022. 63: 140.
https://www.ncbi.nlm.nih.gov/pubmed/35244987
352.Solsona, E., et al. Sequential combination of mitomycin C plus bacillus Calmette-Guerin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial. Eur Urol, 2015. 67: 508.
https://www.ncbi.nlm.nih.gov/pubmed/25301758
353.Cui, J., et al. Combination of Intravesical Chemotherapy and Bacillus Calmette-Guerin Versus Bacillus Calmette-Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis. Medicine (Baltimore), 2016. 95: e2572.
https://www.ncbi.nlm.nih.gov/pubmed/26817914
354.Huang, D., et al. Combination of Intravesical Bacille Calmette-Guerin and Chemotherapy vs. Bacille Calmette-Guerin Alone in Non-muscle Invasive Bladder Cancer: A Meta-Analysis. Front Oncol, 2019. 9: 121.
https://www.ncbi.nlm.nih.gov/pubmed/30881921
355.Shepherd, A.R., et al. Intravesical Bacillus Calmette-Guerin with interferon-alpha versus intravesical Bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer. Cochrane Database Syst Rev, 2017. 3: CD012112.
https://www.ncbi.nlm.nih.gov/pubmed/28268259
356.Jarvinen, R., et al. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guerin (BCG) or alternating BCG and interferon-alpha2b instillations: prospective randomised FinnBladder-4 study. Eur Urol, 2015. 68: 611.
https://www.ncbi.nlm.nih.gov/pubmed/25748117
357.Marttila, T., et al. Intravesical Bacillus Calmette-Guerin Versus Combination of Epirubicin and Interferon-alpha2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study. Eur Urol, 2016. 70: 341.
https://www.ncbi.nlm.nih.gov/pubmed/27085624
358.Delto, J. Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer.pdf>. Oncotarget, 2013.
359.Steinberg, R.L., et al. Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2015. 1: 65.
https://www.ncbi.nlm.nih.gov/pubmed/30561441
360.McElree, I.M., et al. Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder Cancer. J Urol, 2022. 208: 969.
https://www.ncbi.nlm.nih.gov/pubmed/35830552
361.Steinberg, R.L., et al. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. J Urol, 2020. 203: 902.
https://www.ncbi.nlm.nih.gov/pubmed/31821066
362.Steinberg, R.L., et al. Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. Urol Oncol, 2022. 40: 9 e1.
https://www.ncbi.nlm.nih.gov/pubmed/34092482
363.McElree, I.M., et al. Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guerin-Naive High-Risk Nonmuscle-Invasive Bladder Cancer. J Urol, 2022. 208: 589.
https://www.ncbi.nlm.nih.gov/pubmed/35892270
364.Jakse, G., et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur Urol, 2001. 40: 144.
https://www.ncbi.nlm.nih.gov/pubmed/11528191
365.Sylvester, R.J., et al. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol, 2005. 174: 86.
https://www.ncbi.nlm.nih.gov/pubmed/15947584
366.Kaasinen, E., et al. Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder. Scand J Urol, 2016. 50: 360.
https://www.ncbi.nlm.nih.gov/pubmed/27603424
367.Solsona, E., et al. Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications. J Urol, 1996. 155: 895.
https://www.ncbi.nlm.nih.gov/pubmed/8583601
368.Sylvester, R.J., et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology, 2005. 66: 90.
https://www.ncbi.nlm.nih.gov/pubmed/16399418
369.Palou, J., et al. Urothelial carcinoma of the prostate. Urology, 2007. 69: 50.
https://www.ncbi.nlm.nih.gov/pubmed/17280908
370.Palou Redorta, J., et al. Intravesical instillations with bacillus calmette-guerin for the treatment of carcinoma in situ involving prostatic ducts. Eur Urol, 2006. 49: 834.
https://www.ncbi.nlm.nih.gov/pubmed/16426729
371.Di Stasi, S.M., et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol, 2011. 12: 871.
https://www.ncbi.nlm.nih.gov/pubmed/21831711
372.Carrion, D.M., et al. The benefit of a neoadjuvant instillation of chemotherapy in non-muscle invasive bladder cancer: Interim analysis of the PRECAVE randomized clinical trial. Arch Esp Urol, 2021. 74: 883.
https://www.ncbi.nlm.nih.gov/pubmed/34726625
373.Lee, H.W., et al. Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study. J Urol, 2023. 209: 131.
https://www.ncbi.nlm.nih.gov/pubmed/36250938
374.Popert, R.J., et al. Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin. Br J Urol, 1994. 74: 195.
https://www.ncbi.nlm.nih.gov/pubmed/7921938
375.Mostafid, A.H., et al. CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer. BJU Int, 2020. 125: 817.
https://www.ncbi.nlm.nih.gov/pubmed/32124514
376.Lindgren, M.S., et al. DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. J Clin Oncol, 2023. 41: 206.
https://www.ncbi.nlm.nih.gov/pubmed/36223555
377.Yanagisawa, T., et al. A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer. Eur Urol Focus, 2023. 9: 463.
https://www.ncbi.nlm.nih.gov/pubmed/36517409
378.Fritsche, H.M., et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol, 2010. 57: 300.
https://www.ncbi.nlm.nih.gov/pubmed/19766384
379.Turker, P., et al. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. BJU Int, 2012. 110: 804.
https://www.ncbi.nlm.nih.gov/pubmed/22321341
380.May, M., et al. Pathological upstaging detected in radical cystectomy procedures is associated with a significantly worse tumour-specific survival rate for patients with clinical T1 urothelial carcinoma of the urinary bladder. Scand J Urol Nephrol, 2011. 45: 251.
https://www.ncbi.nlm.nih.gov/pubmed/21388337
381.Svatek, R.S., et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int, 2011. 107: 898.
https://www.ncbi.nlm.nih.gov/pubmed/21244604
382.Shariat, S.F., et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol, 2007. 51: 137.
https://www.ncbi.nlm.nih.gov/pubmed/16793197
383.Moschini, M., et al. Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy. BJU Int, 2016. 117: 604.
https://www.ncbi.nlm.nih.gov/pubmed/25851271
384.Schrier, B.P., et al. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol, 2004. 45: 292.
https://www.ncbi.nlm.nih.gov/pubmed/15036673
385.Kamat, A.M., et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol, 2006. 175: 881.
https://www.ncbi.nlm.nih.gov/pubmed/16469571
386.Raj, G.V., et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol, 2007. 177: 1283.
https://www.ncbi.nlm.nih.gov/pubmed/17382713
387.Stein, J.P., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol, 2001. 19: 666.
https://www.ncbi.nlm.nih.gov/pubmed/11157016
388.Hautmann, R.E., et al. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol, 2012. 61: 1039.
https://www.ncbi.nlm.nih.gov/pubmed/22381169
389.Shariat, S.F., et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol, 2006. 176: 2414.
https://www.ncbi.nlm.nih.gov/pubmed/17085118
390.Kurpad, R., et al. A multidisciplinary approach to the management of urologic malignancies: does it influence diagnostic and treatment decisions? Urol Oncol, 2011. 29: 378.
https://www.ncbi.nlm.nih.gov/pubmed/19576797
391.Wayment, R.O., et al. Second opinion pathology in tertiary care of patients with urologic malignancies. Urol Oncol, 2011. 29: 194.
https://www.ncbi.nlm.nih.gov/pubmed/19523859
392.Traboulsi, S.L., et al. Pathology review impacts clinical management of patients with T1-T2 bladder cancer. Can Urol Assoc J, 2017. 11: 188.
https://www.ncbi.nlm.nih.gov/pubmed/28652877
393.Luchey, A.M., et al. Change in Management Based on Pathologic Second Opinion Among Bladder Cancer Patients Presenting to a Comprehensive Cancer Center: Implications for Clinical Practice. Urology, 2016. 93: 130.
https://www.ncbi.nlm.nih.gov/pubmed/27041469
394.Herr, H.W., et al. BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study. Urol Oncol, 2015. 33: 108 e1.
https://www.ncbi.nlm.nih.gov/pubmed/25813144
395.Lerner, S.P., et al. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol, 2009. 27: 155.
https://www.ncbi.nlm.nih.gov/pubmed/18367117
396.Kamat, A.M., et al. Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. J Clin Oncol, 2016. 34: 1935.
https://www.ncbi.nlm.nih.gov/pubmed/26811532
397.U.S. Department of Health and Human Services Food and Drug Administration. BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment Guidance for Industry. Center for Drug Evaluation and Research (CDER). . Center for Biologics Evaluation and Research (CBER), 2018.
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM529600.pdf
398.Roumiguie, M., et al. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guerin-exposed High-risk Non-muscle-invasive Bladder Cancer. Eur Urol, 2022. 82: 34.
https://www.ncbi.nlm.nih.gov/pubmed/34955291
399.Gallagher, B.L., et al. Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy. Urology, 2008. 71: 297.
https://www.ncbi.nlm.nih.gov/pubmed/18308107
400.Herr, H.W., et al. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol, 2003. 169: 1706.
https://www.ncbi.nlm.nih.gov/pubmed/12686813
401.van den Bosch, S., et al. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol, 2011. 60: 493.
https://www.ncbi.nlm.nih.gov/pubmed/21664041
402.Cockerill, P.A., et al. Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer. BJU Int, 2016. 117: 456.
https://www.ncbi.nlm.nih.gov/pubmed/25682834
403.Barlow, L., et al. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guerin therapy. BJU Int, 2009. 104: 1098.
https://www.ncbi.nlm.nih.gov/pubmed/19389012
404.Steinberg, G., et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol, 2000. 163: 761.
https://www.ncbi.nlm.nih.gov/pubmed/10687972
405.Jones, G., et al. Intravesical gemcitabine for non-muscle invasive bladder cancer. Cochrane Database Syst Rev, 2012. 1: CD009294.
https://www.ncbi.nlm.nih.gov/pubmed/22259002
406.Nativ, O., et al. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol, 2009. 182: 1313.
https://www.ncbi.nlm.nih.gov/pubmed/19683278
407.Racioppi, M., et al. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes. BMC Cancer, 2018. 18: 1224.
https://www.ncbi.nlm.nih.gov/pubmed/30522445
408.Tan, W.S., et al. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guerin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guerin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. Eur Urol, 2019. 75: 63.
https://www.ncbi.nlm.nih.gov/pubmed/30274699
409.Morales, A., et al. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guerin. J Urol, 2015. 193: 1135.
https://www.ncbi.nlm.nih.gov/pubmed/25286009
410.Joudi, F.N., et al. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol, 2006. 24: 344.
https://www.ncbi.nlm.nih.gov/pubmed/16818189
411.Wright, K.M. FDA Approves Pembrolizumab for BCG-Unresponsive NMIBC. Oncology (Williston Park), 2020. 34: 44.
https://www.ncbi.nlm.nih.gov/pubmed/32645193
412.Shore, N.D., et al. Intravesical rAd-IFNalpha/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol, 2017. 35: 3410.
https://www.ncbi.nlm.nih.gov/pubmed/28834453
413.Packiam, V.T., et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. Urol Oncol, 2018. 36: 440.
https://www.ncbi.nlm.nih.gov/pubmed/28755959
414.Hassler, M.R., et al. Salvage therapeutic strategies for bacillus Calmette-Guerin failure. Curr Opin Urol, 2019. 29: 239.
https://www.ncbi.nlm.nih.gov/pubmed/30762670
415.Balar, A.V., et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol, 2021. 22: 919.
https://www.ncbi.nlm.nih.gov/pubmed/34051177
416.Boorjian, S.A., et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol, 2021. 22: 107.
https://www.ncbi.nlm.nih.gov/pubmed/33253641
417.Mitra, A.P., et al. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol, 2022. 81: 223.
https://www.ncbi.nlm.nih.gov/pubmed/34933753
418.Hahn, N.M., et al. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. Eur Urol, 2023. 83: 486.
https://www.ncbi.nlm.nih.gov/pubmed/36717286
419.Chamie, K., et al. IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer. NEJM Evid, 2022.
https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200167
420.Kamat, A.M., et al. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. Eur Urol Oncol, 2020. 3: 318.
https://www.ncbi.nlm.nih.gov/pubmed/32201133
421.Li, R., et al. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guerin. Eur Urol, 2020. 78: 387.
https://www.ncbi.nlm.nih.gov/pubmed/32143924
422.Rosevear, H.M., et al. Factors affecting response to bacillus Calmette-Guerin plus interferon for urothelial carcinoma in situ. J Urol, 2011. 186: 817.
https://www.ncbi.nlm.nih.gov/pubmed/21788050
423.Soukup, V., et al. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur Urol, 2012. 62: 290.
https://www.ncbi.nlm.nih.gov/pubmed/22609313
424.Gofrit, O.N., et al. Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur Urol, 2006. 49: 303.
https://www.ncbi.nlm.nih.gov/pubmed/16413659
425.Olsen, L.H., et al. Prolonging follow-up intervals for non-invasive bladder tumors: a randomized controlled trial. Scand J Urol Nephrol Suppl, 1995. 172: 33.
https://www.ncbi.nlm.nih.gov/pubmed/8578253
426.Mariappan, P., et al. The Scottish Bladder Cancer Quality Performance Indicators Influencing Outcomes, Prognosis, and Surveillance (Scot BC Quality OPS) Clinical Project. Eur Urol Focus, 2021. 7: 905.
https://www.ncbi.nlm.nih.gov/pubmed/34419380
427.Holmang, S., et al. Should follow-up cystoscopy in bacillus Calmette-Guerin-treated patients continue after five tumour-free years? Eur Urol, 2012. 61: 503.
https://www.ncbi.nlm.nih.gov/pubmed/22119022
428.Subiela, J.D., et al. Long-term Recurrence and Progression Patterns in a Contemporary Series of Patients with Carcinoma In Situ of the Bladder With or Without Associated Ta/T1 Disease Treated with Bacillus Calmette-Guerin: Implications for Risk-adapted Follow-up. Eur Urol Focus, 2023. 9: 325.
https://www.ncbi.nlm.nih.gov/pubmed/36163105
429.Herr, H.W. Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol, 1998. 16: 1099.
https://www.ncbi.nlm.nih.gov/pubmed/9508196
430.Lotan, Y., et al. Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer. BJU Int, 2021. 127: 108.
https://www.ncbi.nlm.nih.gov/pubmed/32648957
431.Chappidi, M.R., et al. Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guerin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons. J Urol, 2022. 207: 534.
https://www.ncbi.nlm.nih.gov/pubmed/34694916
432.Tschirdewahn, S., et al. Narrow-band imaging assisted cystoscopy in the follow-up of patients with transitional cell carcinoma of the bladder: a randomized study in comparison with white light cystoscopy. World J Urol, 2020. 38: 1509.
https://www.ncbi.nlm.nih.gov/pubmed/31471739
433.Babjuk, M., et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology, 2008. 71: 718.
https://www.ncbi.nlm.nih.gov/pubmed/18387400
434.Niwa, N., et al. Comparison of outcomes between ultrasonography and cystoscopy in the surveillance of patients with initially diagnosed TaG1-2 bladder cancers: A matched-pair analysis. Urol Oncol, 2015. 33: 386 e15.
https://www.ncbi.nlm.nih.gov/pubmed/26027764
435.Laukhtina, E., et al. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. Eur Urol Oncol, 2021. 4: 927.
https://www.ncbi.nlm.nih.gov/pubmed/34753702
436.van Rhijn, B.W., et al. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol, 2005. 47: 736.
https://www.ncbi.nlm.nih.gov/pubmed/15925067
437.Cowan, B., et al. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert((R)) Bladder Cancer Monitor ) for surveillance in patients with non-muscle-invasive bladder cancer. BJU Int, 2021. 128: 713.
https://www.ncbi.nlm.nih.gov/pubmed/33793062
438.Fasulo, V., et al. Xpert Bladder Cancer Monitor May Avoid Cystoscopies in Patients Under “Active Surveillance” for Recurrent Bladder Cancer (BIAS Project): Longitudinal Cohort Study. Front Oncol, 2022. 12: 832835.
https://www.ncbi.nlm.nih.gov/pubmed/35155263
439.Pierconti, F., et al. The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma. Urol Oncol, 2022. 40: 108 e19.
https://www.ncbi.nlm.nih.gov/pubmed/34903453
440.Nayak, A., et al. Quality of life in patients undergoing surveillance for non-muscle invasive bladder cancer-a systematic review. Transl Androl Urol, 2021. 10: 2737.
https://www.ncbi.nlm.nih.gov/pubmed/34295759
441.Public Health England. Living with and beyond bladder cancer - A descriptive summary of responses to a pilot of Patient Reported Outcome Measures for bladder cancer. 2015.
https://www.england.nhs.uk/wp-content/uploads/2015/10/proms-bladder-cancer.pdf
442.Mason, S.J., et al. Evaluating patient-reported outcome measures (PROMs) for bladder cancer: a systematic review using the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist. BJU Int, 2018. 122: 760.
https://www.ncbi.nlm.nih.gov/pubmed/29726085
443.Mariappan, P. Propensity for Quality: No Longer a Tenuous Proposition in Bladder Cancer. Eur Urol, 2020. 78: 60.
https://www.ncbi.nlm.nih.gov/pubmed/32444262
444.Akand, M., et al. Quality Control Indicators for Transurethral Resection of Non-Muscle-Invasive Bladder Cancer. Clin Genitourin Cancer, 2019. 17: e784.
https://www.ncbi.nlm.nih.gov/pubmed/31097388
445.Khare, S.R., et al. Quality indicators in the management of bladder cancer: A modified Delphi study. Urol Oncol, 2017. 35: 328.
https://www.ncbi.nlm.nih.gov/pubmed/28065393
446.Leow, J.J., et al. Quality Indicators for Bladder Cancer Services: A Collaborative Review. Eur Urol, 2020. 78: 43.
https://www.ncbi.nlm.nih.gov/pubmed/31563501
447.NHS National Services Scotland. Bladder Cancer Quality Performance Indicators - Patients diagnosed between April 2014 and March 2017. 2018.